/

Empresas

Ad

No verificado

Aditxt, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosSaludSanidad

57 Comunicados de prensa

Ver todos los comunicados de prensa

13/03/2026

Eventos

Mercado de valores

Ciencia

Biotecnología

Medicina - Varios

Farmacéutica

Salud

Oncología

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Fuente

Editor

1.00

0

05/03/2026

Finanzas

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

Fuente

Editor

1.00

0

18/11/2025

Técnica

Salud

Finanzas

Sanidad

Asociaciones/Profesionales

Oncología

Ciencia

Software

Acciones y Obligaciones

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing

Fuente

Editor

1.00

0

29/10/2025

Salud

Ciencia

Farmacéutica

Biotecnología

Finanzas

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Fuente

Editor

1.00

0

27/10/2025

Sanidad

Ir de compras

Salud

Medicina - Varios

Industria

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Fuente

Editor

1.00

0

25/08/2025

Salud

Higiene alimentaria

Biotecnología

Medicina - Varios

Farmacéutica

Industria

Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Fuente

Editor

1.00

0

11/08/2025

Asociaciones/Profesionales

Salud

Biotecnología

Mercado laboral

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Fuente

Editor

1.00

0

29/07/2025

Biotecnología

Salud

Oncología

Acciones y Obligaciones

Mercado laboral

Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Fuente

Editor

1.00

0

24/07/2025

Oncología

Salud

Ir de compras

Biotecnología

Eventos

Industria

Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Fuente

Editor

1.00

0

22/07/2025

Biotecnología

Salud

Ciencia

Medicina - Varios

Web y redes sociales

Eventos

Aditxt to Present at Wall Street Reporter’s Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0